Zimbabwe has declined a major American health deal worth 367 million US dollars (£272m) over five years over the United States' request for confidential data.
This rejection came to light after a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
A government spokesman later clarified that the US was requesting biological samples for scientific study and commercial purposes while was unwilling to share the benefits from any future treatments.
"We must now begin the challenging and unfortunate task of winding down our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further negotiations to secure a deal suitable to both sides so the country's vital HIV programme can continue.
Broader Background
This development follows a comparable case in neighbouring Kenya, where a high court suspended a similar deal with the US after legal challenges were raised about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government deals to boost transparency and accountability.
Based on reports, Sixteen nations in Africa have to date signed these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, with no corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that provided information," he stated.
"In essence, our nation would provide the raw materials for scientific discovery with no certainty that the end products would be available to our population if a future health crisis emerge."
National Interest and Global Health
He also pointed out that the American exit from the global health body and its pursuit of one-on-one deals were undermining structures already set up through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This system is designed to guarantee that when a country provides its information, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration might be arranged in a way that respects the sovereignty and interests of each country."
Health Experts Response
Medical experts stated it recognised the government's concerns, but suggested that negotiations need to persist since a large portion of the country's HIV programmes depended on foreign aid.
"In cases where technical issues exist, such as those relating to information security or implementation frameworks, these can frequently be resolved through technical clarification and negotiated safeguards," the group added.
The situation emphasises the ongoing challenges between accepting much-needed foreign assistance and safeguarding local interests in an ever more interconnected world.